Batten Disease (NCL) Clinical Trials and Treatments

Batten disease encompasses a group of rare lysosomal storage disorders caused by mutations in genes affecting cellular waste disposal (particularly CLN genes), leading to accumulation of lipofuscin (age pigment) in neurons and other cells. The juvenile-onset form is most common, typically presenting ages 4-8 with progressive vision loss due to retinal degeneration, often beginning with night blindness. Seizures develop in the first few years after symptom onset, initially focal but often progressing to generalized and drug-resistant seizures.

The most common symptoms of Batten Disease include Progressive vision loss starting with night blindness, Blindness usually by teenage years, Seizures, often progressive and drug-resistant, Cognitive decline and behavioral changes, Movement problems, ataxia, and dystonia, among others. Approximately 2-4 per 100,000 births in the U.S.; higher in certain populations (e.g., northern Europe). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Batten Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Batten disease research has made remarkable progress, with FDA-approved enzyme replacement therapy (cerliponase alfa/Brineura) now available for the CLN2 form, given into the fluid spaces of the brain. Other types are being studied too, though most of these studies are not taking new patients.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Batten Disease: Brineura (cerliponase alfa). Corticosteroids and immune globulins count once each.

Batten Disease is caused by variants in any of many genes, most often CLN3, TPP1, PPT1, CLN5, CLN6 and MFSD8. Pathogenic variants in about 12 genes cause the neuronal ceroid lipofuscinoses; all are autosomal recessive except DNAJC5-related CLN4 disease (autosomal dominant). Juvenile-onset CLN3 disease is the most common form.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. Approximately 2-4 per 100,000 births in the U.S.; higher in certain populations (e.g., northern Europe). A multigene panel identifies the cause in most families.

Yes. Batten Disease can be caused by variants in many different genes (CLN3, TPP1, PPT1, CLN5, CLN6 and MFSD8 are among the most common), so testing is usually a multigene panel or exome sequencing rather than one gene at a time. Pathogenic variants in about 12 genes cause the neuronal ceroid lipofuscinoses; all are autosomal recessive except DNAJC5-related CLN4 disease (autosomal dominant). Juvenile-onset CLN3 disease is the most common form.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

Knowing the exact gene matters: it decides which trials a patient qualifies for and which relatives should be tested. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Batten Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Batten Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.